These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10529381)

  • 21. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation.
    Losen M; Martínez-Martínez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH
    Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired rippling muscle disease associated with mild myasthenia gravis: a case report.
    van Schaik SM; Kwa VI; van der Kooi AJ
    J Neurol; 2009 Jul; 256(7):1187-8. PubMed ID: 19277764
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical evaluation and management of myasthenia gravis.
    Keesey JC
    Muscle Nerve; 2004 Apr; 29(4):484-505. PubMed ID: 15052614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults.
    Dubey D; Beecher G; Hammami MB; Knight AM; Liewluck T; Triplett J; Datta A; Dasari S; Zhang Y; Roforth MM; Jerde CR; Murphy SJ; Litchy WJ; Amato A; Lennon VA; McKeon A; Mills JR; Pittock SJ; Milone M
    JAMA Neurol; 2022 Aug; 79(8):808-816. PubMed ID: 35696196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis.
    Somnier FE; Skeie GO; Aarli JA; Trojaborg W
    Eur J Neurol; 1999 Sep; 6(5):555-63. PubMed ID: 10457388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
    Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
    Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
    Farrugia ME; Kennett RP; Hilton-Jones D; Newsom-Davis J; Vincent A
    Clin Neurophysiol; 2007 Feb; 118(2):269-77. PubMed ID: 17157556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification of myasthenia gravis based on autoantibody status.
    Suzuki S; Utsugisawa K; Nagane Y; Satoh T; Terayama Y; Suzuki N; Kuwana M
    Arch Neurol; 2007 Aug; 64(8):1121-4. PubMed ID: 17698702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.
    Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ
    J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rippling muscles and myasthenia gravis with rippling muscles.
    Ansevin CF; Agamanolis DP
    Arch Neurol; 1996 Feb; 53(2):197-9. PubMed ID: 8639072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Muscle lymphocytic infiltrates in thymoma-associated myasthenia gravis are phenotypically different from those in polymyositis.
    Zamecnik J; Vesely D; Jakubicka B; Simkova L; Pitha J; Schutzner J; Mazanec R; Vogel H
    Neuromuscul Disord; 2007 Dec; 17(11-12):935-42. PubMed ID: 17651972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlating extent of neuromuscular instability with acetylcholine receptor antibodies.
    Farrugia ME; Jacob S; Sarrigiannis PG; Kennett RP
    Muscle Nerve; 2009 Apr; 39(4):489-93. PubMed ID: 19260064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis.
    Takamori M
    J Neuroimmunol; 2008 Aug; 200(1-2):142-4. PubMed ID: 18602703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [On the problem of the immunopathogenesis of myasthenia gravis: studies on organ specificity and antigenicity of human and animal skeletal muscle protein].
    Ricken D; Stroehmann I; Aulepp H
    Verh Dtsch Ges Inn Med; 1968; 74():500-3. PubMed ID: 4977256
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seronegative myasthenia gravis.
    Vincent A; McConville J; Farrugia ME; Newsom-Davis J
    Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
    Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P
    Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rippling muscle disease may be caused by "silent" action potentials in the tubular system of skeletal muscle fibers.
    Lamb GD
    Muscle Nerve; 2005 May; 31(5):652-8. PubMed ID: 15742369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thymectomy and muscle antibodies in myasthenia gravis].
    Romi F; Gilhus NE; Aarli JA
    Tidsskr Nor Laegeforen; 2004 Mar; 124(5):629-31. PubMed ID: 15004605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The evidence of antibodies against motor endplates of the skeletal muscle in myasthenia gravis with the double immune-fluorescence technique (author's transl)].
    Storch W; Trautmann B
    Acta Histochem; 1981; 69(1):18-22. PubMed ID: 6795885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.